Metabasis, Sankyo diabetes option deal

Metabasis (San Diego, Calif.) granted Sankyo (Tokyo, Japan) an exclusive option to partner with Metabasis to co-discover and develop a second-generation gluconeogenesis inhibitor to treat Type II diab...